Nebenwirkungen · Trulicity
Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen Trulicity 3 mg solution for injection in pre-filled pen Trulicity 4.5 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 10
HOS-130071 · Präparat HOS-096833
In a phase 3 study through to week 52, when dulaglutide 1.5 mg, 3 mg and 4.5 mg were used in combination with metformin, the incidences of documented symptomatic hypoglycaemia were 3.1 %, 2.4 % and 3.1 %, respectively, and rates were 0.07, 0.05 and 0.07 events/patient/year; one episode of severe hypoglycaemia was reported with dulaglutide 1.5 mg and 4.5 mg, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-30T14:51:00Z · SHA-256 8f7c34e4753bded4db7c0494f49b503f91f5736e3b7e360143648c1ad38b32e3 · Passage 1987dede4c1fd82b9c830fc984eebf1133991ddc3ca2bcbdd7025a889ff7a769 · Zeichen 6023–6396 im Abschnitt